|Bid||70.60 x 100|
|Ask||72.00 x 1500|
|Day's Range||70.56 - 72.48|
|52 Week Range||37.35 - 75.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||88.85|
SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) were published in the Journal of Clinical Psychiatry1. The once-daily 80 mg and 40 mg doses of INGREZZA continued to maintain symptom improvement and were generally well-tolerated over long-term dosing in patients with TD, a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. "We are pleased with the long-term data, which demonstrate the ability of INGREZZA to effectively improve the symptoms of tardive dyskinesia with durable response," said Christopher O'Brien, M.D., Chief Medical Officer of Neurocrine Biosciences.
SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, was awarded the 2017 Pantheon DiNA Award for Outstanding Therapeutic Product by the California Life Sciences Association (CLSA). CLSA is the state's largest and most influential life sciences advocacy and business leadership organization. CLSA will honor this year's winners at the 2017 Pantheon DiNA Awards ceremony on Friday, November 10, at the Marriott Marquis in San Francisco.
Live Audio Webcast Will be on November 16, 2017 SAN DIEGO , Nov. 8, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2017 London Healthcare Conference at 11:20 ...
SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the 2017 Neuroscience Education Institute Congress to be held November 8-12 in Colorado Springs, Colorado. Data being presented include analyses from the RE-KINECT study, a real-world screening study and registry that describes the presence and impact of involuntary movements in patients taking antipsychotics, as well as pooled data analyses from INGREZZA clinical studies across patient sub-groups. "We are pleased to share findings on the impact of tardive dyskinesia, which is characterized by uncontrollable, abnormal and repetitive movements, on real-world patients," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine.
Neurocrine charged many patients twice the price of the drug in the latest quarter—but it is coming to an end.
NEW YORK, NY / ACCESSWIRE / November 3, 2017 / Neurocrine Biosciences was a big mover on Thursday, even hitting a new high after outstanding third quarter results and impressive INGREZZA sales. Alnylam ...
On November 1, 2017, Neurocrine Biosciences, Inc. (NBIX) announced financial results for the third quarter of 2017 and provided a business update. The company reported $45.8 million in revenues from the sale of INGREZZA® for the treatment of tardive dyskinesia (TD), which was way ahead of even the most optimistic expectations. On October 5, 2017, the company announced that the FDA approved the 80 mg capsule of INGREZZA®.
The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX )'s third-quarter results . Given the buoyancy surrounding Ingrezza, ...
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
Neurocrine Biosciences, Juno Therapeutics and Exelixis topped expectations, though Clovis Oncology lagged.
On a per-share basis, the San Diego-based company said it had a loss of 13 cents. The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research ...
- INGREZZA® (valbenazine) Net Product Sales of $45.8 Million for Initial Full Quarter of Commercialization as the First U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia ...
NEW YORK, NY / ACCESSWIRE / November 1, 2017 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 1, 2017 at 5:00 PM ...
- In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse - No new safety concerns were identified ...
Live Audio Webcast Will be on November 8, 2017 SAN DIEGO , Oct. 31, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, will ...
LONDON, UK / ACCESSWIRE / October 30, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AbbVie Inc. (NYSE: ABBV ), following which we have published ...
SAN DIEGO, Oct. 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it has initiated a Phase IIb clinical trial, T-Force GOLD, for INGREZZA® (valbenazine), a novel selective vesicular monoamine transporter 2 (VMAT2) inhibitor, in children and adolescents with Tourette syndrome. Tourette syndrome is a neurological disorder that becomes evident in early childhood or adolescence and is characterized by motor and vocal tics. "We are committed to continuing studies of INGREZZA in patients with neurological disorders including pediatric patients with Tourette syndrome," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences.